SCHEMBL862622

SCHEMBL862622

CS(=O)(=O)NC(=O)c1c(-c2ccc[nH]c2=O)c2cc(Cl)ccc2n1Cc1ccc(F)c(F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C8 P10632 1/20 0.42
KMT2A Q03164 7/20 0.41
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
PPARG P37231 3/20 0.40
CCR2 P41597 1/20 0.38
RCE1 Q9Y256 1/20 0.38
PTGDR2 Q9Y5Y4 2/20 0.37
MCL1 Q07820 1/20 0.37
MEN1 O00255 3/20 0.37
S1PR3 Q99500 2/20 0.36
MAPK8 P45983 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
HPGD P15428 1/20 0.36
MAPT P10636 2/20 0.36
CYP3A4 P08684 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL862487 0.94 CYP2C8 (0.45) CYP2C8KMT2APTGS1PTGS2PPARG
SCHEMBL862037 0.94 KMT2A (0.44) CYP2C8KMT2APTGS1PTGS2PPARG
SCHEMBL862183 0.94 CYP2C8 (0.46) CYP2C8KMT2APPARGCCR2RCE1
SCHEMBL862375 0.93 KMT2A (0.44) CYP2C8KMT2APTGS1PTGS2PPARG
SCHEMBL862140 0.92 KMT2A (0.47) CYP2C8KMT2APPARGCCR2RCE1
SCHEMBL862156 0.92 KMT2A (0.42) CYP2C8KMT2APPARGCCR2RCE1
SCHEMBL862357 0.92 KMT2A (0.44) CYP2C8KMT2APTGS1PPARGCCR2
SCHEMBL862067 0.91 KMT2A (0.50) CYP2C8KMT2APPARGCCR2RCE1
SCHEMBL862324 0.91 KMT2A (0.42) CYP2C8KMT2APTGS2PPARGCCR2
SCHEMBL862086 0.91 KMT2A (0.42) CYP2C8KMT2APPARGCCR2RCE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 CYP2C8 847/4885KMT2A 321/4885PTGS1 2063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.